![]() |
市场调查报告书
商品编码
1820286
临床实验室服务市场规模、份额、趋势及预测(按测试类型、服务提供者、应用和地区划分),2025 年至 2033 年Clinical Laboratory Services Market Size, Share, Trends and Forecast by Test Type, Service Provider, Application, and Region, 2025-2033 |
2024 年全球临床实验室服务市场规模为 2,569 亿美元。展望未来, IMARC Group估计到 2033 年市场规模将达到 3,918 亿美元,2025-2033 年期间的复合年增长率为 4.80%。北美目前占据市场主导地位,2024 年的市占率将超过 39.2%。对血糖测试、糖化血红蛋白测试和血脂分析等诊断测试的需求不断增长,以管理糖尿病,对远距医疗获取临床实验室服务的依赖日益增加,因为它可以减少医疗保健障碍并增加整体测试量,精准医疗的增长趋势正在积极推动临床实验室服务市场份额的增长。
临床实验室服务市场受多种关键因素驱动。全球慢性病和传染病负担日益加重,需要早期精准诊断,这推动了实验室检测的需求。自动化、分子诊断和人工智慧工具等技术进步提高了检测的精确度、速度和效率,从而提升了整体服务水准。人口老化加剧,更容易出现健康问题,进一步推动了对定期和专业检测的需求。预防性医疗保健和健康筛检意识的增强也促进了市场扩张。此外,个人化医疗和伴随诊断的成长也增加了对先进实验室服务的需求。政府措施、医疗服务可近性的改善以及医疗保险覆盖范围的扩大,进一步支持了临床实验室在现代医疗保健中日益重要的角色。
美国临床实验室服务市场的成长得益于癌症、糖尿病和心血管疾病等慢性疾病的日益流行,这刺激了对诊断检测的需求。包括分子诊断和自动化在内的实验室技术的进步正在提高检测准确性并缩短週转时间。人口老化、健康意识的增强以及对预防保健的重视,进一步加速了对常规和专业实验室服务的需求。此外,不断扩大的保险覆盖范围和政府对早期疾病检测的支持也促进了市场的成长。个人化医疗的兴起也推动了美国对先进临床实验室检测的需求。例如,2024年6月,美国实验室服务公司Labcorp推出了Labcorp Global Trial Connect,这是一套中央实验室解决方案,旨在加快临床试验,尤其是在研究者所在地的临床试验。这套数字和资料解决方案旨在提高试验效率,最大限度地减少资料滞后,并简化研究者的工作流程。 Labcorp中央实验室的现有客户可以使用它,并旨在加快临床试验的启动,维持研究进度并提高试验效率。
临床实验室服务市场趋势
糖尿病盛行率上升
为了管理糖尿病,对诊断测试的需求日益增长,包括糖化血红蛋白 (HbA1c) 检测、血糖检测和血脂谱分析。这些测试对于诊断糖尿病、监测血糖水平以及评估相关的心血管风险因素也至关重要。为了有效管理糖尿病,需要定期监测血糖值。临床实验室至关重要,因为它们可以帮助监测血糖控制、肾功能、血脂水平和其他生物标记。为了预防糖尿病视网膜病变、肾病变和神经病变等併发症,临床实验室会进行筛检测试。这些筛检测试可以及时干预,有助于防止糖尿病进展。人们更喜欢即时检测 (POCT),因为它可以快速检测并立即获得结果。这种测试对于监测糖尿病患者更为有效。根据 IDF 糖尿病地图集网站上发布的资料,预计到 2045 年,将有约 7.83 亿人罹患糖尿病。
精准医疗需求不断成长
IMARC集团的报告显示,2023年全球精准医疗市场规模将达752亿美元。基因检测、基因组定序和分子诊断对于精准医疗至关重要,因为它们能够识别生物标记、基因变异和特定的分子标靶。根据临床实验室服务市场预测,这些检测在临床实验室进行,有助于预测疾病风险、根据个别基因特征选择最有效的治疗方法,并指导治疗决策。对于伴随诊断的开发和实施,临床实验室至关重要,这正在促进市场成长。伴随诊断用于识别生物标誌物,以计算任何特定标靶治疗的成功率。了解了这一点,肿瘤学、传染病和其他治疗领域的治疗方案就可以优化。分析基因变异对于监测个体对药物的反应至关重要,而药物基因体学在这项分析中扮演重要角色。临床实验室提供药物基因组学检测,以预测药物疗效、剂量需求和潜在的不良反应。
远距医疗的趋势日益增长
如今,人们更青睐远距医疗,因为即使身处偏远地区,也能与医生取得联繫。他们还可以透过远距医疗平台存取临床实验室服务,从而减少就医门槛,并提高整体检测量。透过远距医疗,远距监测糖尿病等慢性疾病变得轻而易举。临床实验室对于持续管理这些疾病并改善患者预后至关重要。远距医疗市场的主要参与者正致力于透过合作和伙伴关係来扩大客户群。例如,2023 年,Zoom Video Communications, Inc. 和甲骨文 (Oracle) 扩大了合作伙伴关係,以提供更快、更简单、更有效率的医疗服务。临床实验室分发家用试剂盒,然后处理在家中采集的样本,透过远距医疗平台远端提供准确的诊断结果,为临床实验室服务市场带来了良好的前景。
The global clinical laboratory services market size was valued at USD 256.9 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 391.8 Billion by 2033, exhibiting a CAGR of 4.80% during 2025-2033. North America currently dominates the market, holding a significant market share of over 39.2% in 2024. The growing demand for diagnostic tests, such as blood glucose tests, HbA1c testing, and lipid profiles to manage diabetes, rising reliance on telehealth to access clinical laboratory services as it can reduce barriers to healthcare and increase overall testing volumes, and the increasing trend of precision medicines are positively fueling the clinical laboratory services market share.
The clinical laboratory services market is driven by several key factors. The rising global burden of chronic and infectious diseases necessitates early and accurate diagnostics, boosting demand for lab testing. Technological advancements, including automation, molecular diagnostics, and AI-based tools, have improved test precision, speed, and efficiency, enhancing overall service delivery. An aging population, more prone to health issues, further drives the need for regular and specialized testing. Increased awareness of preventive healthcare and wellness screenings also contributes to market expansion. Moreover, the growth of personalized medicine and companion diagnostics has increased the demand for advanced laboratory services. Government initiatives, improved healthcare access, and the expansion of health insurance coverage additionally support the growing role of clinical laboratories in modern healthcare.
The clinical laboratory services market growth in the United States is fueled by the rising prevalence of chronic diseases like cancer, diabetes, and cardiovascular disorders, which is fueling the demand for diagnostic testing. Advancements in laboratory technologies, including molecular diagnostics and automation, are enhancing test accuracy and turnaround times. An aging population, growing health awareness, and the emphasis on preventive care are further accelerating the need for routine and specialized lab services. Additionally, expanding insurance coverage and government support for early disease detection contribute to market growth. The rise of personalized medicine also drives demand for advanced clinical laboratory testing in the U.S. For instance, in June 2024, the US laboratory services firm Labcorp introduced Labcorp Global Trial Connect, a collection of central laboratory solutions aimed at speeding up clinical trials, especially at investigator locations. The collection of digital and data solutions seeks to improve trial efficiency, minimize data lags, and simplify workflows at investigator sites. It is accessible to current clients of Labcorp Central Laboratory and aims to accelerate the initiation of clinical trials, sustain study progress, and improve trial efficiency.
Clinical Laboratory Services Market Trends
Rising prevalence of diabetes
There is a rise in the demand for diagnostic tests, including HbA1c testing, blood glucose tests, and lipid profiles, to manage diabetes. These tests are also crucial for diagnosing diabetes, monitoring blood sugar levels, and assessing associated cardiovascular risk factors. To effectively manage diabetes, there is a need to monitor blood glucose levels regularly. Clinical laboratories are very essential as they can help in monitoring glycemic control, kidney function, lipid levels, and other biomarkers. For preventing complications, such as diabetic retinopathy, nephropathy, and neuropathy, clinical laboratories perform screening tests. These screening tests allow for timely intervention that can assist in preventing progression of diabetes. People prefer point-of-care testing (POCT) as it allows rapid testing and immediate results. This testing is more successful for monitoring patients with diabetes. As per the data published on the website of IDF Diabetes Atlas, it is projected that around 783 million people will be suffering from diabetes by 2045.
Growing demand for precision medicine
The IMARC Group's report shows that the global precision medicine market reached USD 75.2 Billion in 2023. Genetic testing, genomic sequencing, and molecular diagnostics are important for precision medicines to identify biomarkers, genetic variations, and specific molecular targets. According to the clinical laboratory services market forecast, these tests are performed in clinical laboratories, as they help in predicting disease risks, selecting the most effective therapies as an individual's genetic characteristic, and guiding treatment decisions. To develop and perform companion diagnostics, clinical laboratories are very crucial, which is strengthening the market growth. Companion diagnostics are tests used to identify biomarkers to calculate the success rate of any specific targeted therapy. After knowing this, treatment choices in oncology, infectious diseases, and other therapeutic areas can be optimized. It is very important to analyze genetic variations to monitor the respond of medications in individuals, and pharmacogenomic plays an important role in this analysis. Clinical laboratories provide pharmacogenomic testing to predict drug efficacy, dosage requirements, and potential adverse reactions.
Increasing trend of telehealth
People prefer telehealth nowadays, as it can help connect with doctors even if they are in remote locations. They can also access clinical laboratory services through telehealth platforms, reducing barriers to healthcare and increasing overall testing volumes. It becomes easy to monitor chronic conditions like diabetes remotely through telehealth. Clinical laboratories are very important for the ongoing management of these diseases and improving patient outcomes. Major players operating in the telehealth market are focusing on collaborations and partnerships to expand their customer base. For instance, in 2023, Zoom Video Communications, Inc. and Oracle extended their partnership to provide healthcare services that are quicker, simpler, and more efficient. Home-based kits are distributed by clinical laboratories, and then they process the samples collected at home to provide accurate diagnostic results remotely through telehealth platforms, thereby offering a favorable clinical laboratory services market outlook.
Clinical chemistry stands as the largest test type in 2024, holding 46.7% of the market share. Clinical chemistry can be defined as a broad range of tests that assess the biochemical components of blood, urine, and other bodily fluids. To diagnose and track a variety of medical disorders, these tests are important as they can provide vital information on hormone levels, organ function, electrolyte balance, and metabolic processes. Regular health screenings and follow-up care for patients with chronic diseases also include many clinical chemistry tests. To evaluate general health status and identify problems, tests such as complete metabolic panels (CMP) and basic metabolic panels (BMP) are frequently ordered.
Hospital-based laboratories lead the market with 53.6% of market share in 2024. Hospital-based laboratories are essential components of healthcare facilities as they are closely linked to the whole range of patient services. Within the hospital setting, they provide diagnostic services for surgical units, outpatient clinics, inpatients, and patients in the emergency room. A wide variety of diagnostic tests are usually available at hospital laboratories to support different patient demographics and medical specialties. Clinical chemistry, hematology, immunology, microbiology, molecular diagnostics, and pathology services are all included in this. They offer a one-stop shop for a variety of diagnostic testing requirements.
Bioanalytical and lab chemistry services lead the market with around 38.6% of market share in 2024. Clinical diagnostics and biomedical research depend heavily on a wide range of tests and analyses that are provided by bioanalytical and lab chemistry services. Assays for biomarkers, drug concentrations, metabolites, and other biochemical components in biological samples are among the services provided by these labs. Pharmacokinetic (PK) and pharmacodynamic (PD) investigations are two important steps in the drug development process that bioanalytical services provide for the pharmaceutical and biotechnology industries. Clinical laboratories offer bioanalytical services for measuring drug concentrations in biological matrices, evaluating medication safety and efficacy in clinical trials, and assessing drug metabolism.
In 2024, North America accounted for the largest market share of over 39.2%. North America has highly developed healthcare systems with cutting-edge infrastructure and widespread access to healthcare services, especially in the United States and Canada. This includes a reputable network of clinics, hospitals, and diagnostic labs that provide a wide range of clinical laboratory services. When it comes to healthcare spending worldwide, the US regularly comes in top. The rapid rise of clinical laboratory services can be attributed to the significant investments made in healthcare infrastructure, technology, and services. The market-driving initiatives of illness monitoring, tailored medication, and diagnostic testing are bolstered by healthcare spending. Key players operating in the US are also focusing on providing tests that support novel technology. For instance, in 2023, Dutch biotech firm Detact Diagnostics' announced about its plans to begin bacterial detection sampling at its laboratory in the Keene State College situated in the US.
United States Clinical Laboratory Services Market Analysis
In 2024, the United States accounted for 88.50% of the clinical laboratory market in North America. The United States is experiencing a surge in clinical laboratory services adoption driven by the increasing trend of telehealth. For instance, more than seven billion clinical lab tests are performed in the U.S. each year, providing critical data for a relatively small expenditure. As more patients access remote consultations and digital health platforms, the demand for timely and accurate diagnostic support continues to expand. Clinical laboratories are playing a central role in supporting these virtual health services, offering integrated test processing and dissemination results through electronic health records and patient portals. The seamless coordination between telehealth providers and diagnostic labs enables faster treatment decisions, improving overall patient management. Healthcare providers increasingly rely on these services to enhance chronic disease monitoring, acute illness diagnosis, and preventive care assessments. This shift aligns with broader digital health adoption and reimbursement frameworks, fueling continued investment in clinical laboratory services infrastructure to meet growing national demand.
Asia Pacific Clinical Laboratory Services Market Analysis
Asia-Pacific is witnessing rising clinical laboratory services adoption due to the growing prevalence of diabetes across the region. For instance, according to a 2023 study by the Indian Council of Medical Research-India Diabetes (ICMR INDIAB), 10.1 crore people have diabetes. This chronic condition demands frequent monitoring and diagnostic interventions, including blood glucose analysis, HbA1c testing, and related screenings. The increasing burden of diabetes is placing clinical laboratories at the forefront of disease management strategies, with healthcare systems integrating regular lab diagnostics into outpatient and community care settings. Additionally, growing health awareness and expanding access to medical facilities contribute to higher test volumes. Patients seek regular monitoring for disease progression and treatment response, pushing laboratories to scale operations. Public and private health institutions are actively expanding their diagnostic capabilities to accommodate this trend, positioning clinical laboratory services as a crucial component in controlling the diabetes epidemic across diverse population groups.
Europe Clinical Laboratory Services Market Analysis
Europe is experiencing a rapid rise in clinical laboratory services adoption, attributed to significant investments made in healthcare infrastructure, technology, and services. For instance, France (11.9%), Germany (12.6%), and Austria (11.2%) had the highest current healthcare spending as a percentage of GDP in 2022 among EU nations. Governments and private entities are channeling resources into modernizing diagnostic capabilities, automating laboratory workflows, and enhancing data interoperability across systems. These upgrades facilitate quicker test results, higher testing volumes, and better integration with healthcare delivery networks. Technological advancements, including molecular diagnostics and high-throughput platforms, are being widely implemented, transforming traditional laboratory environments into dynamic hubs for precision medicine. Additionally, healthcare policy reforms are supporting broader access to diagnostic services, encouraging regular screenings and early disease detection.
Latin America Clinical Laboratory Services Market Analysis
Latin America is expanding its clinical laboratory services adoption in response to increasing healthcare facilities and privatization. The National Confederation of Health (CNSaude) and the Brazilian Federation of Hospitals (FBH) report that 62% of Brazil's 7,191 hospitals are private. As private healthcare providers enter the market, investments in diagnostic capabilities grow, leading to a rise in clinical lab testing volumes. Enhanced infrastructure, supported by modern diagnostic tools and expanding hospital networks, is improving access to laboratory services. This growth aligns with rising demand from patients utilizing healthcare facilities more frequently, including those relying on routine and preventive care. The privatization trend is accelerating service quality improvements.
Middle East and Africa Clinical Laboratory Services Market Analysis
The Middle East and Africa are observing greater clinical laboratory services adoption due to rising demand for diagnostic tests such as blood glucose tests, HbA1c testing, and lipid profiles. For instance, the International Diabetes Federation (IDF) reports that the prevalence of diabetes is 9.3% globally and 16.3% in the United Arab Emirates. Growing awareness of chronic diseases and preventive care is prompting individuals to seek early and accurate diagnosis. Health systems across the region are strengthening diagnostic capabilities to meet increasing test volumes. Expanding access to primary care and diagnostic services is positioning clinical laboratories as key players in disease monitoring and treatment support.
Leading clinical laboratory services companies are aggressively pursuing a range of tactics to fortify their positions in the market and satisfy the expanding need for diagnostic tests. Businesses are reaching more patients worldwide and providing a wider choice of tests by partnering with other companies and increasing their service portfolios through acquisitions. For instance, in 2023, Tufts Medicine, a preeminent integrated academic health system in Massachusetts, and Labcorp, a global leader in innovative and comprehensive laboratory services, announced an agreement to purchase the Tufts Medicine outreach laboratory business and certain operating assets as a precursor to a more extensive strategic partnership. Major firms are also making significant investments in cutting-edge technologies including automation, digital pathology, and next-generation sequencing to increase the precision, effectiveness, and turnaround times of their services. By creating and utilizing specific tests for genetic and molecular diagnostics, they are also concentrating on customized medicine, which supports precision medicine and focused therapeutics.